SNGX SOLIGENIX INC US FDA Inspections 8-K Filing 2024 - Other Events Soligenix, Inc. announced the receipt of agreement from the European Medicines Agency for a Phase 3 study on HyBryte in the treatment of cutaneous T-cell lymphoma patients.Get access to all SEC 8-K filings of the SOLIGENIX INC